This study aimed to compare the use of financial agreements for oncology and non-oncology appraisals...
Read moreThis study from 2017 - 2019 compares the outcomes for oncology and non-oncology appraisals conducted...
Read moreIn England, to gain a positive recommendation for use within the NHS from NICE, pharmaceutical produ...
Read moreNICE will continue to offer joint advice with the Medicines and Healthcare products Regulatory Agenc...
Read moreNICE was the first EU HTA body to provide their assessment of Kymriah for ALL, publishing their opin...
Read moreInitially NICE rejected Illumetri for not being cost-effective, but a new negotiated price means th...
Read moreSpeaking at the international pharma conference, NICE’s chief executive Sir Andrew Dillon struck a...
Read moreA new game changing treatment for people with multiple myeloma will now be available on the NHS in E...
Read moreConclusion: Blincyto has significant clinical benefits, but that further evidence on cost-effective...
Read moreNHS England continues to develop its pricing and reimbursement expertise by appointing Blake Dark, a...
Read more